These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31414546)

  • 21. Core promoter mutations of hepatitis B virus and hepatocellular carcinoma: story beyond A1762T/G1764A mutations.
    Liu CJ; Kao JH
    J Gastroenterol Hepatol; 2008 Mar; 23(3):347-50. PubMed ID: 18318819
    [No Abstract]   [Full Text] [Related]  

  • 22. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
    Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
    Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
    [No Abstract]   [Full Text] [Related]  

  • 23. What can we learn from hepatitis B virus clinical cohorts?
    Lin CL; Tseng TC; Kao JH
    Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal observation of viral load changes in untreated HBeAg negative chronic hepatitis B.
    Croagh CM; Bell SJ; Chen RY; Locarnini S; Desmond PV
    Acta Gastroenterol Belg; 2013 Sep; 76(3):275-81. PubMed ID: 24261020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?
    Chun HS; Lee M
    Clin Mol Hepatol; 2021 Jul; 27(3):448-450. PubMed ID: 34157831
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk stratification for hepatitis B virus related hepatocellular carcinoma.
    Lin CL; Kao JH
    J Gastroenterol Hepatol; 2013 Jan; 28(1):10-7. PubMed ID: 23094699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load.
    Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    Hepatology; 2012 Jan; 55(1):68-76. PubMed ID: 21858846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia.
    Elkady A; Tanaka Y; Kurbanov F; Oynsuren T; Mizokami M
    J Gastroenterol Hepatol; 2008 Mar; 23(3):474-81. PubMed ID: 18318825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
    Chen CJ; Yang HI; Su J; Jen CL; You SL; Lu SN; Huang GT; Iloeje UH;
    JAMA; 2006 Jan; 295(1):65-73. PubMed ID: 16391218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.
    Ormeci A; Aydın Y; Sumnu A; Baran B; Soyer OM; Pınarbasi B; Gokturk S; Gulluoglu M; Onel D; Badur S; Akyuz F; Karaca C; Demir K; Besisik F; Kaymakoglu S
    Int J Infect Dis; 2016 Nov; 52():68-73. PubMed ID: 27619844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. e-antigen-negative chronic hepatitis B in Bangladesh.
    Ahmad N; Alam S; Mustafa G; Adnan AB; Baig RH; Khan M
    Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):379-82. PubMed ID: 18693173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B.
    ter Borg MJ; Hansen BE; Bigot G; Haagmans BL; Janssen HL
    J Clin Virol; 2008 Jun; 42(2):160-4. PubMed ID: 18359663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotyping and molecular characterization of hepatitis B virus in liver disease patients in Kenya.
    Ochwoto M; Chauhan R; Gopalakrishnan D; Chen CY; Ng'ang'a Z; Okoth F; Kioko H; Kimotho J; Kaiguri P; Kramvis A
    Infect Genet Evol; 2013 Dec; 20():103-10. PubMed ID: 23978387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma.
    Pellicelli AM; Vignally P; Messina V; Izzi A; Mazzoni E; Barlattani A; Bacca D; Romano M; Mecenate F; Stroffolini T; Furlan C; Picardi A; Gentilucci UV; Gulminetti R; Bonaventura ME; Villani R; D'Ambrosio C; Paffetti A; Mastropietro C; Marignani M; Fondacaro L; Cerasari G; Andreoli A; Barbarini G
    Ann Hepatol; 2014; 13(4):376-85. PubMed ID: 24927608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
    Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads.
    Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Hsu CA; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    Hepatology; 2013 Feb; 57(2):441-50. PubMed ID: 22941922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis B e antigen and the risk of hepatocellular carcinoma.
    Yang HI; Lu SN; Liaw YF; You SL; Sun CA; Wang LY; Hsiao CK; Chen PJ; Chen DS; Chen CJ;
    N Engl J Med; 2002 Jul; 347(3):168-74. PubMed ID: 12124405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic hepatitis B in pregnant women: is hepatitis B surface antigen quantification useful for viral load prediction?
    Fujiko M; Chalid MT; Turyadi ; Ie SI; Maghfira ; Syafri ; Wahyuni R; Roni M; Patellongi I; Massi MN; Muljono DH
    Int J Infect Dis; 2015 Dec; 41():83-9. PubMed ID: 26571304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Authors' reply.
    Kim GA; Lim YS
    Aliment Pharmacol Ther; 2020 Aug; 52(3):576-577. PubMed ID: 32656844
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.